תוצאות חיפוש - Matko Kalac

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma

    Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma מאת Jennifer E. Amengual, Sean Clark-Garvey, Matko Kalac, Luigi Scotto, Enrica Marchi, Ellen Neylon, Paul Johannet, Ying Wei, Jasmine Zain, Owen A. O’Connor

    יצא לאור 2013
    קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  2. 2
    Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma

    Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma מאת Matko Kalac, Salvia Jain, Constantine S. Tam, Zhengrui Xiao, Francesca Montanari, Jennifer A. Kanakry, Bryan D. Huber, Mendel Goldfinger, Owen A. O’Connor, Enrica Marchi

    יצא לאור 2023
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  3. 3
    HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

    HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL מאת Matko Kalac, Luigi Scotto, Enrica Marchi, Jennifer E. Amengual, Venkatraman Seshan, Govind Bhagat, Netha Ulahannan, Violetta V. Leshchenko, Alexis M. Temkin, Samir Parekh, Benjamin Tycko, Owen A. O’Connor

    יצא לאור 2011
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  4. 4
    A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma

    A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma מאת Jennifer E. Amengual, Renee Lichtenstein, Jennifer Kimberly Lue, Ahmed Sawas, Changchun Deng, Emily Lichtenstein, Karen Khan, Laine E. Atkins, Aishling M. Rada, Hye A. Kim, Codruța Chiuzan, Matko Kalac, Enrica Marchi, Lorenzo Falchi, Mark A. Francescone, Lawrence Schwartz, Serge Cremers, Owen A. O’Connor

    יצא לאור 2017
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  5. 5
    Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial

    Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial מאת Owen A. O’Connor, Jennifer Kimberly Lue, Ahmed Sawas, Jennifer E. Amengual, Changchun Deng, Matko Kalac, Lorenzo Falchi, Enrica Marchi, Ithamar Turenne, Renee Lichtenstein, Celeste Rojas, Mark Francescone, Lawrence H. Schwartz, Bin Cheng, Kerry J. Savage, Diego Villa, Michael Crump, Anca Prica, Vishal Kukreti, Serge Cremers, Joseph M. Connors, John Kuruvilla

    יצא לאור 2017
    קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:

כלי חיפוש: